How can the In vitro diagnostics industry tap the growth potential of intergrated delivery networks?

Integrated delivery networks (IDNs) provide healthcare across the continuum for a geographic region. Typically, they include hospitals and provider networks and may include skilled nursing or long-term rehab facilities, specialty clinics, and home health services. Usually, but not always, the health system supports a self-insured health insurance plan. Kaiser Permanente, Geisinger, and Intermountain Health are just a few of the more well-known IDNs.

All healthcare providers and hospitals, including those that are part of IDNs, are facing increased financial pressure to deliver measurable, high-quality care to patients, by reducing preventable hospital readmissions or post-surgical infections, for example. For fiscal year 2017, CMS is reducing reimbursements for more than 2,500 hospitals due to higher than expected readmissions within 30 days of discharge for six conditions and for 769 hospitals with the highest rates of hospital-acquired infections . But IDNs, particularly those with self-insured health plans, are uniquely positioned to reap the financial benefits of initiatives that rely heavily on remote patient monitoring and telehealth to keep patients out of the hospital and in better health.

In vitro diagnostics (IVDs) can play a substantial role in these endeavors. IVDs are medical devices, which include reagents, instruments, and assays used to analyze human samples. They can be used to diagnose a disease, predict disease progression, or select therapy. IVDs range in complexity from simple blood test to check cholesterol levels to whole genome sequencing used to identify the underlying genetic cause of a disorder.

The rest of my piece is published here:

Sorry for the redirection, but since it is being published I want to make sure I point everyone in the right direction. If you do like the piece, please let me know here and I can write more on this topic or similar topics.